|
FY2025
12 months to Dec 28, 2025
|
FY2024
12 months to Dec 29, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Cash flows from operating activities from continuing operations | |||||
| Net loss | |||||
| Loss from discontinued operations, net of income taxes | |||||
| Net loss from continuing operations, net of tax | |||||
| Adjustments to reconcile net loss from continuing operations to net cash used in operating activities: | |||||
| Formation cost paid by related party | |||||
| Stock-based compensation expense | |||||
| Non-cash lease expense | |||||
| Depreciation and amortization | |||||
| Amortization of debt issuance costs | |||||
| Deferred income tax provision | |||||
| Provision for credit losses | |||||
| Loss on CS Solis debt extinguishment | |||||
| Change in reserve for excess and obsolete inventory | |||||
| Loss on sale of equity securities | |||||
| Change in fair value of SAFE Agreements with related party | |||||
| Loss on conversion of SAFE Agreements to shares of common stock with related party | |||||
| Change in fair value of deferred consideration | |||||
| Loss on issuance of derivative liability | |||||
| Change in fair value of derivative liabilities | |||||
| Issuance of forward purchase agreements | |||||
| Loss on issuance of common stock in connection with forward purchase agreements | |||||
| Change in fair value of forward purchase agreement liabilities | |||||
| Non-cash expense in connection with warrants issued for vendor services | |||||
| Loss on impairments and disposals | |||||
| Loss on issuance of common stock bonus shares in connection with the Mergers | |||||
| Issuance of restricted stock units in connection with vendor services | |||||
| Non-cash income | |||||
| Non-cash interest expense | |||||
| Gain on troubled debt restructuring | |||||
| Accretion of debt in CS Solis | |||||
| Other financing costs | |||||
| Changes in operating assets and liabilities, net of acquisitions: | |||||
| Accounts receivable | |||||
| Contract assets, current portion | |||||
| Net cash provided by operating activities from discontinued operations | |||||
| Inventories | |||||
| Prepaid expenses and other current assets | |||||
| Other noncurrent assets | |||||
| Accounts payable | |||||
| Accrued expenses and other current liabilities | |||||
| Operating lease liabilities | |||||
| Warranty provision, noncurrent | |||||
| Contract liabilities | |||||
| Net cash used in operating activities from continuing operations | |||||
| Cash flows from investing activities from continuing operations | |||||
| Purchases of property and equipment | |||||
| Capitalization of internal-use-software costs | |||||
| Cash paid for acquisitions; net of cash acquired | |||||
| Proceeds from the sale of equity securities | |||||
| Net cash used in investing activities from continuing operations | |||||
| Proceeds from issuance of Private Placement Warrants | |||||
| Cash flows from financing activities from continuing operations | |||||
| Proceeds from issuance of notes payable, net of issuance cost | |||||
| Proceeds from issuance of convertible notes, net of issuance cost | |||||
| Proceeds from issuance of convertible notes to related parties | |||||
| Payment of debt issuance costs | |||||
| Proceeds from issuance of SAFE agreements with related party | |||||
| Proceeds from issuance of common stock | |||||
| Proceeds from exercise of common stock options | |||||
| Proceeds from exercise of warrant for common stock | |||||
| Investor financing deposit – related party | |||||
| Taxes paid related to net share settlement of equity awards | |||||
| Principal repayment of notes payable | |||||
| Proceeds from issuance of SAFE agreements | |||||
| Proceeds from Mergers and PIPE Financing | |||||
| Proceeds from Mergers and PIPE Financing from related parties | |||||
| Financing lease payments | |||||
| Net cash provided by financing activities from continuing operations | |||||
| Effect of exchange rate changes | |||||
| Effect of exchange rate changes on cash | |||||
| Net increase (decrease) in cash, cash equivalents and restricted cash | |||||
| Cash, cash equivalents, and restricted cash at beginning of period | |||||
| Cash, cash equivalents, and restricted cash at end of period | |||||
| Supplemental disclosures of cash flow information: | |||||
| Cash paid during the year for interest | |||||
| Cash paid during the year for income taxes | |||||
| Supplemental schedule of noncash investing and financing activities: | |||||
| Cancellation of existing indebtedness in Exchange Agreement | |||||
| Issuance of convertible notes in Exchange Agreement | |||||
| Issuance of common stock in Exchange Agreement | |||||
| Conversion of SAFE Agreements to shares of common stock – related party | |||||
| Operating lease right-of-use assets obtained in exchange for new operating lease liabilities | |||||
| Offering costs | |||||
| Warrants issued in debt issuance | |||||
| Carlyle Warrant modification – related party | |||||
| Conversion of 2022 Convertible notes into common stock | |||||
| Issuance of common stock warrants | |||||
| Conversion of 2022 Convertible Notes issued to related parties into common stock | |||||
| Conversion of preferred stock into common stock | |||||
| Issuance of common stock in connection with forward purchase agreements | |||||
| Loss on issuance of common stock bonus shares in connection with the Mergers(6) | |||||
| Issuance of common stock bonus shares in connection with the Mergers | |||||
| Recapitalization of Legacy Complete Solaria Common stock into Complete Solaria Common Stock | |||||
| Reclassification of investor deposit to PIPE funds | |||||
| Reclassification of warrants between liabilities and equity | |||||
| Issuance of Seller Note as partial purchase consideration for acquisition of Sunder(8) | |||||
| Issuance of common stock as partial consideration for acquisition of Sunder | |||||
| Deferred consideration recognized for acquisition of Sunder | |||||
| Issuance of common stock as partial purchase consideration for acquisition of Ambia | |||||
| Deferred consideration recognized for acquisition of Ambia | |||||
| Conversion of September 2024 Notes to shares of common stock: | |||||
| September 2024 Notes and related derivative liability, net of unamortized debt discount | |||||
| Accrued interest | |||||
| Common stock | |||||
| Additional paid-in capital | |||||
| Debt issuance costs incurred in connection with the issuance of September 2025 Notes | |||||
| Taxes accrued but unpaid related to net share settlement of equity awards | |||||
| Cancellation of existing indebtedness in Exchange Agreement | |||||
| Issuance of convertible notes in Exchange Agreement | |||||
| Issuance of common stock in Exchange Agreement | |||||
| Conversion of SAFE Agreements to shares of common stock – related party | |||||
| Operating lease right-of-use assets obtained in exchange for new operating lease liabilities | |||||
| Offering costs | |||||
| Warrants issued in debt issuance | |||||
| Carlyle Warrant modification – related party | |||||
Loading...